Hyper Pigmentation - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hyper Pigmentation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hyper Pigmentation - Pipeline Review, H2 2014', provides an overview of the Hyper Pigmentation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyper Pigmentation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyper Pigmentation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyper Pigmentation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyper Pigmentation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyper Pigmentation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyper Pigmentation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyper Pigmentation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyper Pigmentation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hyper Pigmentation Overview 6
Therapeutics Development 7
Pipeline Products for Hyper Pigmentation - Overview 7
Pipeline Products for Hyper Pigmentation - Comparative Analysis 8
Hyper Pigmentation - Therapeutics under Development by Companies 9
Hyper Pigmentation - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Hyper Pigmentation - Products under Development by Companies 13
Hyper Pigmentation - Companies Involved in Therapeutics Development 14
Kasiak Research Pvt. Ltd. 14
MediQuest Therapeutics, Inc. 15
RXi Pharmaceuticals Corporation 16
Hyper Pigmentation - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
MQX-054 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NPH-29 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Refaglo - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TRY-26071 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TRY-26077 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Number of Products under Development for Hyper Pigmentation, H2 2014 7
Number of Products under Development for Hyper Pigmentation - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Hyper Pigmentation - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 14
Hyper Pigmentation - Pipeline by MediQuest Therapeutics, Inc., H2 2014 15
Hyper Pigmentation - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25